Nevertheless, primate models permit useful testing of potential AMD treatments and therapies and investigations of the underlying etiology for AMD. The macaque model already has been used to evaluate novel photodynamic therapy (PDT) agents, including verteporfin (Visudyne; Novartis AG, Basel, Switzerland.),
18 19 20 21 63 mono-
l-aspartyl chlorin e6 (NPe6; Meiji Seika Kaisha, Ltd., Tokyo, Japan),
64 65 66 ATX-S10(Na) (Photochemical Inc., Okayama, Japan),
43 67 and motexafin lutetium (Optrin; Pharmacyclics Inc., Sunnyvale, CA), whereas the squirrel monkey model has been used in the testing of the MV6401 agent (PhotoPoint; Miravant Pharmaceuticals Inc., Santa Barbara, CA) (Pratt LM, et al.
IOVS 2001;42:ARVO Abstract 2353; Ciulla TA, et al.
IOVS 2002:43:ARVO E-Abstract 614).
68 Diffuse FVT offer special opportunities to evaluate neovascularization and potential methods for treatment in areas of the choroid and retina that were initially unaffected by laser photocoagulation. There also is evidence to suggest that some squirrel monkeys may have retinal degenerations, with characteristics similar to those associated with retinitis pigmentosa,
69 whereas some very old animals (older than 10 years) exhibit vascular changes that are characteristic of macular degeneration (Criswell M, et al., unpublished results, 2001). Finally, a current investigation that compares CNV growth factor expression with molecular and immunocytochemical techniques in the rat CNV laser trauma model (Hu W, et al.
IOVS 2003;44:ARVO E-Abstract 3937; Criswell M, et al. unpublished results, 2003) also will include primate tissues as they become available for such analyses.